

Prognostic Clinical and Biological Markers for Amyotrophic Lateral Sclerosis Disease Progression: Validation and Implications for Clinical Trial Design and Analysis

Authors: Michael Benatar¹, Eric A Macklin², Andrea Malaspina³, Mary-Louise Rogers⁴, Eran Hornstein⁵, Vittoria Lombardi³, Danielle Renfrey⁴, Stephanie Shepheard⁴, Iddo Magen⁵, Yahel Cohen⁵, Volkan Granit¹, Jeffrey M Statland⁶, Jeannine M Heckmann⁷, Rosa Rademakers^{8,9}, Caroline A McHutchison^{10,11}, Leonard Petrucelli⁹, Corey T McMillan¹², and Joanne Wu¹ on behalf of the CReATe Consortium PGB1 Study Investigators

Affiliations:

¹ Department of Neurology, University of Miami Miller School of Medicine, Miami, FL, USA

² Departments of Neurology and Medicine, Massachusetts General Hospital, Harvard Medical School, Boston, MA USA

³ UCL Queen Square Motor Neuron Disease Center, UCL Queen Square Institute of Neurology, University College London, Queen Square, London, UK

⁴ Flinders Health and Medical Research Institute, College of Medicine and Public Health, Flinders University, Adelaide, South Australia, Australia

⁵ Department of Molecular Genetics and Molecular Neuroscience, Weizmann Institute of Science, Israel

⁶ Department of Neurology, University of Kansas Medical Center, Kansas City, KS USA

⁷ Division of Neurology, Department of Medicine, University of Cape Town, South Africa

⁸ VIB Center for Molecular Neurology, Department of Biomedical Sciences, University of Antwerp, Antwerp, Belgium

⁹ Department of Neuroscience, Mayo Clinic, Jacksonville, Florida, USA

¹⁰ School of Philosophy, Psychology, and Language Sciences, The University of Edinburgh, Edinburgh, UK.

¹¹ Euan MacDonald Centre for Motor Neuron Disease Research, The University of Edinburgh, Edinburgh, UK

¹² Department of Neurology, University of Pennsylvania Perelman School of Medicine, Philadelphia, PA, USA

Correspondence to: Michael Benatar MD, PhD, or Joanne Wu, ScM, Department of Neurology, University of Miami Miller School of Medicine, 1120 NW 14 Street, CRB Suite 1300, Miami, FL, 33136, USA. Email: mbenatar@miami.edu; or jwu@miami.edu.

Structured Summary (max 300)

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34

Background. With increasing recognition of the value of incorporating prognostic markers into amyotrophic lateral sclerosis (ALS) trial design and analysis plans, there is a pressing need to understand *which* among the prevailing clinical and biochemical markers have real value, and *how* they can be optimally used.

Methods. A subset of patients with ALS recruited through the multi-center Phenotype-Genotype-Biomarker study (clinicaltrials.gov: NCT02327845) was identified as “trial-like” based on meeting common trial eligibility criteria. Clinical phenotyping was performed by evaluators trained in relevant assessments. Serum neurofilament light (NfL) and phosphorylated neurofilament heavy (pNfH), urinary p75^{ECD}, plasma microRNA-181, and an array of biochemical and clinical measures were evaluated for their prognostic value. Associations with functional progression were estimated by random-slopes mixed models of ALS functional rating scale-revised (ALSFRS-R) score. Associations with survival were estimated by log-rank test and Cox proportional hazards regression. Potential sample size savings from adjusting for given biomarkers in a hypothetical trial were estimated.

Findings. Baseline serum NfL is a powerful prognostic biomarker, predicting survival and ALSFRS-R rate of decline. Serum NfL <40pg/ml and >100pg/ml correspond to future ALSFRS-R slopes of ~0.5 and 1.5 points/month, respectively. Serum NfL also adds value to the best available clinical predictors, encapsulated by the European Network to Cure ALS (ENCALS) predictor score. In models of functional decline, the addition of NfL yields ~25% sample size saving above those achieved by inclusion of either clinical predictors or ENCALs score alone. The prognostic value of serum pNfH, urinary p75^{ECD}, and plasma miR-181ab is more limited.

Interpretation. Among the multitude of biomarkers considered, only blood NfL adds value to the ENCALs prediction model and should be incorporated into analysis plans for all ongoing and future ALS trials. Defined thresholds of NfL might also be used in trial design, for enrichment or stratified randomisation, to improve trial efficiency.

Funding. NIH (U01-NS107027, U54-NS092091). ALSA (16-TACL-242).

Key Words: Prognostic biomarkers, Context-of-use, ALS clinical trials, Neurofilament

35 **Research in Context**

36

37 Evidence Before This Study

38 The phenotypic heterogeneity of ALS poses a challenge for clinical trials, making it more difficult
39 to discern therapeutic effects of investigational agents amidst the noise of natural variability.
40 Prognostic markers are important tools to help mitigate this issue. A host of clinical markers and
41 putative biomarkers have been proposed to have prognostic value, but their relative utility,
42 especially when considered jointly, and the practical implications of their use, have not been well
43 defined.

44

45 Added Value of This Study

46 Using a trial-like population from a natural history study, in which clinical trial-grade phenotypic
47 data and multi-modal biomarker data were collected, we show that a subset of clinical factors,
48 encapsulated by the ENCALS predictive model score, and serum neurofilament light chain (NfL)
49 are the most powerful prognostic markers when considering either ALSFRS-R functional decline
50 or permanent assisted ventilation (PAV)/tracheostomy-free survival. Importantly, serum NfL adds
51 prognostic value even after adjusting for the ENCALS score, yielding an additional sample size
52 saving of ~27% in a hypothetical future clinical trial. While serum phosphorylated neurofilament
53 heavy chain (pNfH), urinary p75^{ECD}, and plasma miR-181ab each holds some prognostic value,
54 when considered together with the ENCALS score and serum NfL, only p75^{ECD} may yield
55 additional but modest sample size saving.

56

57 Implication of All Available Evidence

58 Blood NfL is a validated biomarker for multiple contexts-of-use. As a prognostic marker, it should
59 be used together with clinical predictors, such as the ENCALS predictive model score, in all
60 ongoing and future ALS clinical trials. The utility of urinary p75^{ECD} and plasma miR-181ab is less
61 clear. Serum pNfH, as well as serum uric acid, albumin, creatinine, and C-reactive protein
62 (CRP), provide no additional prognostic information.

63

64 **Introduction**

65 Clinical trials in the field of amyotrophic lateral sclerosis (ALS) must consider the phenotypic
66 heterogeneity of disease as well as the related challenge that clinically meaningful outcomes,
67 such as the rate of functional decline and survival, are typically insufficiently sensitive to detect
68 therapeutic effect in the early- and mid-phases of drug development. Biofluid biomarkers that
69 are fit-for-purpose, however, may help to meaningfully address this problem.¹ In patients with
70 clinically manifest ALS (as opposed to the pre-symptomatic population at elevated risk for ALS,
71 which is beyond the scope of this paper), *prognostic biomarkers* might be used in three broad
72 ways to improve the design and analysis of clinical trials. From a study design perspective, they
73 may be used as eligibility criteria to enrich for a population, in which a therapeutic effect might
74 be most apparent, or to stratify randomisation. They may also be used analytically to adjust for
75 phenotypic heterogeneity, thereby reducing the sample size needed to adequately power a trial
76 using clinical outcome measures.² These approaches are not mutually exclusive, and indeed
77 could be combined, depending on the goals of a particular trial. In addition, *response*
78 *biomarkers* might be used to demonstrate target engagement or pharmacodynamic effect, and
79 perhaps even serve as surrogates that are reasonably likely to predict a future clinical benefit.

80
81 There remains, however, a significant gap between biomarker discovery, analytic validation, and
82 preliminary reports of biomarker performance in samples of convenience on the one hand, and
83 clinical validation on the other hand. The latter entails demonstrating the utility of a biomarker for
84 a well-defined context-of-use in a large, carefully phenotyped clinical cohort.

85
86 Prior studies have identified clinical parameters predictive of disease progression² or survival.^{2,3}
87 Moreover, among patients with ALS, neurofilament light chain (NfL) has emerged as the lead
88 prognostic and response biomarker⁴⁻⁸ for a number of reasons: NfL can reliably be measured
89 in blood, there is a high correlation between blood and cerebrospinal fluid (CSF) concentrations,
90 and empiric data support these contexts-of-use based on results from serum or plasma. There
91 is, however, also persistent interest in the potential prognostic value of other biomarkers,
92 including blood phosphorylated neurofilament heavy chain (pNfH),⁹ urinary p75 neurotrophin
93 receptor extracellular domain (p75^{ECD}),¹⁰ microRNA-181 (miR-181),¹¹ and an array of analytes,
94 such as uric acid,¹²⁻²⁰ albumin,¹⁶ creatinine,^{16,20,21} and C-reactive protein (CRP),^{8,22,23} that are
95 routinely quantified in the clinical arena.

96

97 In this study, we sought to clinically validate the utility of putative prognostic biofluid biomarkers
98 in the context of established clinical prognostic factors. The rationale is that a prognostic
99 biomarker would only be worth quantifying if it adds value to what can be learned from known
100 and readily available clinical parameters. Furthermore, a head-to-head comparison of clinical
101 markers and molecular biomarkers revealed their relative contributions to clinical trial design,
102 analysis, and result interpretation. Finally, we characterised the longitudinal trajectories of a
103 subset of biomarkers, to inform their potential future use as response biomarkers. While
104 prognostic clinical measures and biomarkers may have value in the clinical arena, such
105 individual use of these markers is beyond the scope of the current investigation which is
106 focused on the clinical trial utility of these markers,

107

108 **Methods**

109 *Study Population*

110 Patients with ALS were enrolled (between 2014 and 2019) at 12 centers in the United States and
111 1 center in South Africa through the prospective Phenotype-Genotype-Biomarker (PGB) study
112 (registered at clinicaltrials.gov NCT02327845) of the Clinical Research in ALS and Related
113 Disorders for Therapeutic Development (CReATe) Consortium. The PGB study enrolled 705
114 patients with ALS (n=472), primary lateral sclerosis (n=47), progressive muscular atrophy
115 (n=20), hereditary spastic paraplegia (n=162) and other related disorders (n=4). The goal was
116 to evaluate participants serially over a period of 1.5-2 years to acquire longitudinal phenotypic
117 data. Those with ALS, ALS-FTD and PMA were to be seen at Baseline, and Months 3, 6, 12 and
118 18; those with PLS, HSP and multisystem proteinopathy were to be seen at Baseline and
119 Months 6, 12, 18 and 24. Biological samples (blood and urine, as well as cerebrospinal fluid
120 when willing) were collected at all study visits. Periodic medical record reviews, in addition to
121 direct communication with patients, were performed as needed to ascertain the timing of
122 survival endpoint (permanent assisted ventilation [PAV; non-invasive ventilation > 23 hours/day],
123 tracheostomy, or death).

124

125 While PGB was designed to be broadly inclusive, the subset of patients with ALS who met
126 common trial eligibility criteria were designated as “trial-like” and served as the basis for this
127 report. Key inclusion/exclusion criteria included: diagnosis of ALS according to El Escorial
128 criteria, permitting those with cognitive or behavioural impairment (ALSci or ALSbi, respectively),
129 but excluding ALS-FTD; less than 3 years from onset of weakness; and an erect slow vital

130 capacity (SVC) of $\geq 50\%$ predicted. All patients with ALS in PGB who met these criteria were
131 included in the current report.

132

133 *Clinical Assessments*

134 The ALS Functional Rating Scale-Revised (ALSFRS-R), a 48-point scale that includes bulbar,
135 gross motor, fine motor, and respiratory domains,²⁴ was the principal measure of functional
136 status. Symptom onset was defined based on the first appearance of weakness or impaired
137 motor function. The estimated rate of change in ALSFRS-R between symptom onset and
138 baseline (Δ FRS), was defined as (48-baseline ALSFRS-R/months since symptom onset).²⁵
139 Respiratory muscle function was quantified with slow vital capacity (SVC) in the erect position.
140 Alternate versions of the North American version of the Edinburgh Cognitive and Behavioural
141 ALS Screen (ECAS), including informant report, was used to evaluate cognitive and behavioural
142 function.²⁶ All evaluators were trained and certified for the performance of each of these
143 outcome measures. Biological sex, as well as race and ethnicity, were self-reported.

144

145 *Ethics*

146 The University of Miami institutional review board (IRB), which served as the central IRB for
147 CReATe, approved the study for all US sites study (protocol # 20160603) and the University of
148 Cape Town Health Sciences Human Research Ethics Committee approved the study in South
149 Africa (REF number 165/2017). All participants provided written informed consent.

150

151 *Biological Samples*

152 Biological specimens were collected, processed, and stored according to strict standard
153 operating procedures. Briefly, blood was collected in serum-separating BD vacutainers and
154 allowed to clot upright at room temperature for 1–2 hours. Following centrifugation (1,750 g for
155 10 min at 4°C), serum was aliquoted into cryogenic sterile freestanding conical microtubes
156 (Nalgene or Bio Plas Inc.) and stored at –80°C. Plasma was collected in K2 EDTA tubes,
157 centrifuged at 1,750g for 10 minutes at 4°C within 2 hours of collection, and aliquoted for
158 storage at –80°C. Urine was collected in a sterile collection cup, gently swirled, and transferred
159 to cryovials for immediate storage at -80°C.

160

161 *Biomarker and Genetic Assays*

162 Serum NfL and pNfH concentrations were quantified using the Simoa NfL and pNfH assays in
163 the laboratory of an author (AM). Established protocols for NfL (Simoa Nf-L Advantage Kit-

164 102258, Quanterix) and pNfH (Simoa pNF-Heavy Discovery Kit - 102669) analysis were used.
165 Each plate contained calibrators and quality controls. Samples were diluted to fall within the
166 range of the standard curve.

167
168 Urinary p75^{ECD} was quantified by ELISA in the laboratory of an author (MLR) as previously
169 described.¹⁰ Briefly, urinary p75^{ECD} was measured by a sandwich ELISA, that used a capture
170 monoclonal antibody (MLR1 at 8mg/ml) made to the extracellular region of p75²⁷ in Carbonate-
171 Carbonate coating buffer (Ph 9.6). Another monoclonal antibody (NGFR5) to p75²⁸ was used as
172 the detection antibody and biotinylated as per the manufacturer's instructions (Thermo Fisher
173 Scientific Australia, #UG283022) and used at 2.0mg/ml in the assay. Human p75^{ECD} standard
174 was from R&D Systems (Lys29-Asn250; #367-NR). BlockAce (BioRad, BUF-029) was used as
175 blocking and sample buffer. The enzyme reaction was achieved using streptavidin horseradish
176 peroxidase (Jackson ImmunoResearch Laboratories, #JIO16030084) diluted to 1.0 mg /ml and
177 colour developed using tetramethylbenzidine (A:B; BioRad Australia, #1721067). The entire
178 ELISA was accomplished as previously described²⁹ on a Hamilton Starlet Robot, integrated
179 with a Biotek 405 washer, and an MD reader (450nm); two calibrator human urine samples with
180 known p75^{ECD} levels were included on each plate, and if the results from either had greater than
181 20% coefficient of variation, the results from the plate were rejected. The results were reported
182 as ng p75^{ECD}/ ml urine and corrected by creatinine (mg/ml; measured by calorimetric method
183 using Enzo Life Sciences Creatinine Kits (ADI-907-030A) as per the manufacturer's
184 instructions). Samples with urinary creatinine below 0.3 ± 0.03 mg/ml or above 3.0 ± 0.3 mg ml
185 were rejected as per World Health Organization guidelines³⁰. Final results are reported as ng
186 p75^{ECD}/mg creatinine.

187
188 Total RNA was extracted from plasma using the miRNeasy Micro Kit (Qiagen cat. 217084) and
189 quantified with a Qubit fluorometer using the RNA Broad Range Assay Kit (Thermo Fisher
190 Scientific cat. Q10210). For small RNA next-generation sequencing, libraries were prepared
191 from 7.5 µg of total RNA using the QIAseq miRNA Library Kit (cat. 331505) and QIAseq miRNA
192 NGS 48 Index IL (Qiagen cat. 331592) by an experimenter who was blinded to the identity of
193 samples. Precise linear quantification of miRNA gained by UMIs of random 12 nucleotides after
194 3' and 5' adapter ligation, within the reverse transcription primers. cDNA libraries were amplified
195 by PCR for 22 cycles, with a 3' primer that includes a six-nucleotide unique index, followed by
196 on-bead size selection and cleaning. Library concentration was determined with a Qubit
197 fluorometer (dsDNA High Sensitivity Assay Kit, Thermo Fisher Scientific, cat. Q32851) and

198 library size with TapeStation D1000 (Agilent, cat. Catalog number: Q32851). Libraries with
199 different indices were multiplexed and sequenced on a NovaSeq SP100 (Illumina), with 75-bp
200 single read and 6-bp index read. Human miRNA sequences were mapped using GeneGlobe
201 (Qiagen), normalized with the DESeq2 package and corrected for the library preparation batch.
202 Plasma miR-181a and miR-181b were quantified by small RNA next-generation sequencing in
203 the laboratory of an author (EH) as previously described,¹¹ and summarised as miR-181ab, the
204 combined expression of miR-181a and miR-181b. Serum uric acid, albumin, creatinine, and
205 CRP were assayed using the Roche Cobas C Analyzer in the Clinical Chemistry Laboratory at
206 the University of Miami. All biomarker studies were performed blind to clinical outcomes.

207
208 The presence of a *C9orf72* repeat expansion was determined in the laboratory of an author
209 (RR) using a two-step protocol, including a fluorescent PCR fragment-length analysis and a
210 repeat-primed PCR, with previously described oligos (ThermoFisher), as described elsewhere.³¹
211 The PCR reactions (Qiagen) for both assays included Betaine and DMSO additives
212 (MilliporeSigma). The FAM labeled products were run on a 3730xl DNA Analyzer (Applied
213 Biosystems) and sized with Genescan 400 using Genemapper software (ThermoFisher).

214
215 *Statistics*

216 Longitudinal change in ALSFRS-R total score, serum NfL, serum pNfH, and urinary p75^{ECD} were
217 estimated in unadjusted mixed model repeated-measures analyses with visits windowed to the
218 closest planned assessment time (at 3, 6, 12, and 18 months) and in unadjusted mixed model
219 random-slopes analyses using the observed assessment times. The repeated-measures model
220 included a fixed effect of visit and assumed unstructured person-level variance-covariance
221 among repeated observations. The random-slopes model included a fixed effect of time and
222 assumed unstructured variance-covariance for the person-level random intercepts and slopes.
223 Biomarker concentrations were log-transformed prior to analysis and estimates were back-
224 transformed. Back-transformation of visit-specific estimates yield values on the original scale of
225 measurement. Back-transformation of slopes or changes from baseline yield geometric mean
226 ratios which were further transformed by subtracting 1 and multiplying by 100 to express as
227 deviations in percentage change from 100%.

228
229 We examined an array of clinical measures (sex, onset age, bulbar onset, diagnostic delay,
230 Δ FRS [estimated rate of change in ALSFRS-R between symptom onset and baseline],²⁵
231 baseline age, ALSFRS-R total score, slow vital capacity, ECAS-derived scores, and ENCALs

232 predictor score) and biofluid biomarkers (serum NfL, serum pNfH, urinary p75^{ECD}, serum uric
233 acid, serum albumin, serum creatinine, serum CRP, plasma miR-181ab) as potential
234 prognostics of rate of disease progression as measured by ALSFRS-R total score and of
235 PAV/tracheostomy-free survival. We derived five scores from baseline ECAS assessments: total
236 score, ALS-specific score, ALS non-specific score, and dichotomous designations of cognitive
237 impairment (ALSci) and behavioural impairment (ALSbi) defined according to the revised Strong
238 criteria³² and implemented in the PGB study.³³ ALSci and ALSbi designations were restricted to
239 English-speaking participants for whom robust normative data permitted reliable designation.²⁶
240 The ENCALS linear predictive model score³ (hereinafter “ENCALS predictor score” or
241 “ENCALS score”) combines information from 8 clinical variables (Δ FRS, bulbar onset,
242 diagnostic delay [months from symptom onset to diagnosis], age at onset, El Escorial definite
243 ALS, presence of FTD, presence of a *C9orf72* repeat expansion, and percent predicted vital
244 capacity). Plasma miR-181ab was evaluated as a continuous measure, split at the median
245 (24,590 UMI in the current study), and as defined by Magen et al¹¹ where miR181-ab was
246 defined as a poor prognostic when above the threshold of 39,300 UMI among those in the
247 middle tertile of NfL concentration (NfL 59-109.8pg/ml)¹¹, and as defined by Magen et al but
248 using the median miR181ab value and the middle NfL tertile (44.8-80.8pg/ml) from the current
249 study.

250
251 Prognostic markers were assessed for their ability to predict the rate of progression in ALSFRS-
252 R total score in random-slopes analyses and to predict PAV/tracheostomy-free survival by
253 Kaplan-Meier product-limit estimates and by Cox proportional hazards regression. In survival
254 analyses, time at risk began at the baseline visit (time zero) and continued to time last known
255 alive or time of PAV, tracheostomy, or death, if observed. Each model included one prognostic.
256 Continuous prognostics were evaluated both as continuous predictors after standardizing to unit
257 variance and when divided into quartiles. We focused on analyses after dividing prognostics into
258 quartiles (or fewer levels – e.g., for binary measures, where only 2 levels are possible) to avoid
259 the strong assumption of a linear association with rate of progression and survival across the full
260 range of a given prognostic and to permit comparison of all prognostics in a common
261 framework. Models were either unadjusted, adjusted for established core clinical predictors
262 (bulbar onset, Δ FRS, and diagnostic delay for functional decline; plus baseline age for survival),
263 adjusted for ENCALS predictor score, or adjusted also for serum NfL. The adjusted models
264 sharpened estimates by accounting for known sources of variation and addressed whether a
265 given prognostic provided new information independent of known predictors of progression and

266 survival. Wald confidence intervals were used for estimates from random-slopes models.

267 Complementary log-log confidence intervals were used for estimates of median survival time.

268 Profile likelihood confidence intervals were used for estimates of hazard ratios.

269

270 In addition to estimating the clinical utility of each potential prognostic biomarker, we quantified
271 the proportional sample size saving that would result from adjusting for a given biomarker in a
272 hypothetical clinical trial. Reductions in sample size requirements based on a normal
273 approximation for a hypothetical clinical trial testing for slowing of ALSFRS-R progression,
274 analyzed in a random slopes model, were estimated based on reductions in standard error
275 estimates of the estimated slopes and resulting increases in the effect size after inclusion of a
276 given prognostic marker as a linear predictor. The proportional savings in sample size assume a
277 consistent but arbitrary allocation ratio, type 1 error control, and power between designs and an
278 assessment schedule similar to the present cohort. For any given choice of allocation ratio, type
279 1 error control, and power, the relative sample size required for two trials with equivalent
280 assessment schedule differs only as a function of the ratio of the respective effect sizes for tests
281 of the primary outcome, in the present case the estimated slope of ALSFRS-R. Note that effect
282 size ratios rather than variance ratios were used due to small variation in estimated slopes when
283 adding covariates.

284

285 A post-hoc analysis of the association between serum NfL and rate of progression in ALSFRS-R
286 total score was performed using a cubic smoothing spline through the empirical Bayes ALSFRS-
287 R slope estimates from an unadjusted random-slopes analysis and using a partial-linear spline
288 in a longitudinal random-slopes analysis. Knots for the partial-linear spline were chosen post-
289 hoc, based on visual inspection, at 40 and 100 pg/mL to approximate the shape of the cubic
290 smoothing spline.

291

292

293 Analyses were performed using SAS (version 9.4, SAS Institute, Cary NC) and R (version 4.0.3,
294 R Foundation for Statistical Computing, Vienna, Austria). Comparison-wise p-values are
295 reported with nominal significance at two-tailed $p < 0.05$. Results significant after correction by
296 Holm-Bonferroni stepdown adjustment for multiple comparisons over 28 prognostic markers are
297 indicated.

298

299 *Role of Funders*

300 The funders of the study had no role in study design, data collection, statistical analysis, results
301 interpretation, or writing of the report.

302

303 **Results**

304 *Study Population*

305 A total of 203 patients with ALS were included, with a mean (\pm SD) age of 57.1 (\pm 12) years and a
306 slight male preponderance (55%). A genetic cause of ALS was identified in 24 (12%), most
307 commonly a *C9orf72* hexanucleotide repeat expansion (n=20; 10%). Median disease duration
308 (time since symptom onset) at baseline was 14.4 months, with a mean SVC of 85% (\pm 17)
309 predicted (Table 1a). ALSFRS-R declined by an average (\pm SE) of 0.89 (\pm 0.05) points/month
310 (Figure 1a) with median (Q1-Q3) follow-up of 10.1 (5.8-16.3) months. SVC declined by an
311 average (\pm SE) of 1.8% (\pm 0.15) predicted per month. 93 (46%) patients reached a survival
312 endpoint (PAV, tracheostomy, or death), with a median (Q1-Q3) survival time of 30.1 (17.4-47.7)
313 months observed from follow-up of 17.4 (10.6-29.9) months. 110 patients were censored (25
314 study completion, 15 loss to follow-up, 11 withdrawal/dropout, and 59 administrative study
315 closure).

316

317 *Biomarker Profiles*

318 Baseline serum NfL concentrations ranged from 9 to 214 pg/mL (Table 1b) and correlated with
319 subsequent rates of ALSFRS-R decline (Spearman $r=-0.57$, 95% CI [-0.66, -0.47], $p<0.0001$,
320 Figure 1b). Over the course of follow-up, serum NfL increased by an average (95% CI) of 0.98%
321 [0.57%, 1.38%] per month (Table 2, Figure 2a). Baseline serum pNfH concentrations ranged
322 from 3.4 to 4,177 pg/mL (Table 1b) and increased by an average of 0.45% [-0.12%, 1.03%] per
323 month (Table 2, Figure 2b). Baseline urinary p75^{ECD} levels ranged from 1.5 to 16.2 ng/mg
324 creatinine (Table 1b) and increased by an average of 2.59% [2.01%, 3.17%] per month (Table 2,
325 Figure 2c). Baseline plasma miR-181ab (product of miR-181a and miR-181b) concentration
326 ranged from 2,875 to 431,004 unique molecular identifiers (UMIs) (Table 1b). Baseline
327 concentrations of serum uric acid, albumin, creatinine, and CRP are summarised in Table 1b.
328 Baseline biomarker results, stratified by *C9orf72* status and by sex are summarised in eTable 1
329 and eTable 2 respectively, with longitudinal changes in biomarkers stratified by sex in eTable 3.
330 Correlations among all prognostics at baseline are summarised in eTable 4.

331

332 *Prognostic Markers for Survival*

333 In univariate models, the strongest predictors of survival were the ENCALS score, baseline
334 serum NfL, and Δ FRS. Median survival among those with ENCALS predictor scores in the
335 lowest vs. highest quartiles (i.e., lowest vs. highest predicted risk of PAV/tracheostomy-free
336 survival) were 48 vs. 17 months (Table 3, Figure 3a). Median survival among those with Δ FRS
337 slopes in the lowest vs. highest quartiles (i.e., slowest vs. fastest pre-baseline slope) were 47
338 vs. 17 months (Table 3, Figure 3b). Median survival among those with baseline NfL
339 concentrations in the lowest vs. highest quartiles were 49 vs. 17 months (Table 3, Figure 3c).
340 Median survival among those with baseline miR181ab above vs. below 24,590 UMI were. 23 vs.
341 35 months (Table 3, Figure 3d). Bulbar onset, baseline ALSFRS-R, and baseline SVC
342 %predicted also predicted survival (Table 3).

343
344 In Cox proportional hazards models of time to death or equivalent, we evaluated the prognostic
345 utility of each clinical and biofluid marker when added as quartiles to multivariate models that
346 included either a core set of clinical predictors (bulbar, Δ FRS, and diagnostic delay) or the
347 ENCALS predictor score (Table 3). Results from models with prognostic measures added as
348 linear terms are summarised in eTable 5. When a given prognostic is included both as quartiles
349 and as a linear term among the covariates, the results presented in Table 3 describe any non-
350 linearity in the relationship with survival. Serum NfL remained the strongest predictor. For
351 example, in a model that already includes the ENCALS predictor score, the hazard ratio (HR)
352 for the fourth vs. first quartile values of NfL is 7.3 (Table 3). The addition of NfL as a linear term
353 to an ENCALS-adjusted Cox model, yields a HR of 1.83 for every 1 standard deviation increase
354 in NfL (eTable 5). To examine the prognostic value of plasma miR-181ab in these multivariate
355 models, we considered multiple analytic approaches. The previously published approach, in
356 which a higher miR-181ab is categorised as poor prognostic only for the middle tertile of NfL¹¹,
357 reveals no prognostic value beyond that conferred by NfL alone, whether tertiles from a prior
358 study or the current cohort were used. By contrast, dichotomising at the median value in this
359 cohort (but not the threshold value identified in a prior study) added some prognostic value –
360 with HRs of 1.65 and 1.73, respectively, when miR-181ab was added to the core set of clinical
361 predictors and the ENCALS predictor score (Table 3). None of the other biomarker candidates
362 considered – serum uric acid, albumin, creatinine, or CRP – added prognostic value in survival
363 analyses (Table 3). Similarly, none of our measures of cognitive/behavioural impairment
364 predicted survival (Table 3).

365
366 *Prognostic Markers for Functional Decline*

367 In univariate random-slope models of ALSFRS-R decline, Δ FRS, diagnostic delay, ENCALS
368 score, baseline NfL, and baseline pNfH were identified as prognostic markers (Table 4).
369 Although not developed for predicting functional decline, the ENCALS model predicted
370 differential rates of disease progression that ranged from -0.57 to -1.27 points/month among
371 those with the lowest vs. highest quartile ENCALS scores (Table 4, unadjusted). NfL is also a
372 powerful predictor of future functional decline, with slopes ranging from -0.41 to -1.49
373 points/month among those with the lowest vs. highest quartiles NfL values (Table 4). Results
374 from models with prognostic measures added as linear terms are summarised in eTable 6.

375
376 In multivariate models that already incorporate the ENCALS predictor score, quartiles of
377 baseline serum NfL added substantial prognostic value, with the rate of ALSFRS-R progression
378 ranging from -0.44 to -1.44 points/month among those with the lowest vs. highest quartile
379 values. Δ FRS and serum pNfH added much less prognostic value. Irrespective of the analytic
380 approach, plasma miR-181ab did not add prognostic value beyond that conferred by serum NfL
381 (Table 4). None of the other clinical markers (including measures of cognitive and behavioural
382 impairment), or biomarker candidates considered added prognostic value in random-slopes
383 models of ALSFRS-R functional decline (Table 4).

384
385 *Impact of Prognostic Markers on Sample Size Savings for Future Clinical Trials*

386 For the outcome measure of ALSFRS-R slope, the ENCALS model yields a 9% sample size
387 saving, compared to 30.9% for NfL alone (Table 5). The combination of ENCALS and NfL yields
388 a ~34% saving in sample size. In random slope models of ALSFRS-R that incorporate either the
389 core clinical predictors plus NfL, or ENCALS predictor score plus NfL, the addition of urinary
390 p75^{ECD} yields an additional ~4% sample size saving, suggesting a modest additional utility of
391 this prognostic marker (with the caveat that this conclusion is based on incomplete baseline
392 data for p75^{ECD} in this sample). The addition of serum pNfH or plasma miR-181ab, however,
393 yielded no additional sample size saving, indicating that in multivariate models that incorporate
394 clinical predictors and NfL, these latter biomarkers add little prognostic value when the ALSFRS-
395 R slope is the outcome measure (Table 5). None of the other clinical measures (including those
396 of cognitive or behavioural impairment) or biomarker candidates yielded sample size savings
397 when considered as prognostic markers.

398
399 *A Practical Approach to Incorporating NfL into Trial Design*

400 The relationship between baseline NfL and future rate of functional decline, as measured by the
401 slope of the ALSFRS-R, is not linear (Figure 1b). In this dataset, the sigmoidal relationship
402 yields an estimate of thresholds that might be used either as eligibility criteria (for trial
403 enrichment) or to facilitate stratifying randomisation (to ensure equal balance of NfL-predicted
404 faster and slower disease progression rates across treatment groups). Baseline NfL levels <40
405 pg/mL corresponded to a future ALSFRS-R slope of ~0.5 points/month (i.e. slow progression),
406 whereas baseline levels >100 pg/mL corresponded to a future ALSFRS-R slope of ~1.5
407 points/month (i.e., fast progression). In the range from 40 to 100 pg/mL, ALSFRS-R slope
408 declines quickly for each incremental increase in baseline serum NfL concentration.

409

410 **Discussion**

411 This study comprehensively evaluated leading biochemical *prognostic* biomarker candidates,
412 alone and in combination, and examined their potential utility when combined with established
413 and emerging clinical predictors. This multivariate approach is essential to achieving a fuller
414 understanding of the practical value of candidate prognostic markers. Moreover, mindful that
415 observational studies typically enroll slower progressing patients, for greatest relevance to the
416 design and analysis of future trials we *a priori* focused our analysis on a trial-like population, the
417 subset of PGB participants who met clinical trial eligibility criteria. Absent a similar biomarker
418 study that utilizes the placebo group from clinical trial(s), our approach is the most robust to date
419 in providing clear answers about the utility of an array of prognostic biomarker candidates.

420

421 Serum NfL is a robust predictor of disease progression, whether the outcome is ALSFRS-R rate
422 of decline or survival time. While the overlap in survival curves for the second and third quartiles
423 of NfL (Figure 3c), for example, suggests limited prognostic value for NfL in the mid-range of
424 values when predicting survival, the relationship between NfL and future rate of functional
425 decline is steepest in the mid-range of values (Figure 1b). Moreover, not only does NfL provide
426 greater prognostic value than the ENCALIS predictor score, the combination of NfL and the
427 ENCALIS score yields more prognostic value than either NfL or ENCALIS score alone. (Of note,
428 we have not fully explored potential transformations of NfL data to optimize its performance as a
429 prognostic marker beyond those displayed in Figure 1. Future research using fractional
430 polynomials or regression splines might further improve the value of NfL as a prognostic³⁴. We
431 also acknowledge that some information is lost by dividing a continuous prognostic into
432 categories and that cut points for quartiles will vary from one dataset to another. The quartiles
433 provided here are intended to be descriptive of potential non-linearity in associations, not to be

434 prescriptive of future handling of such prognostics.) Serum pNfH, on the other hand, has some
435 prognostic value for functional decline, but not survival; and in models already adjusting for
436 clinical predictor(s) and NfL, it yielded no additional prognostic value. The prognostic utility of
437 urinary p75^{ECD} and plasma miR-181ab are more nuanced, with p75^{ECD} yielding some sample
438 size saving when combined with clinical predictor(s) and NfL (recognizing that this conclusion is
439 based on incomplete baseline data for p75^{ECD} in this sample). Serum uric acid, albumin,
440 creatinine, and CRP have no value as prognostic biomarkers irrespective of the outcome used.
441 Similarly, baseline cognitive and behavioural impairment, based on the ECAS, does not add
442 prognostic value.

443
444 While the greater prognostic value of blood NfL (than pNfH) may reflect a more critical role for
445 the NfL isoform in maintaining neuroaxonal structure and function under pathological conditions,
446 this may also reflect the better analytic performance of the blood NfL immunoassay. pNfH
447 assays in blood are still hampered by a matrix effect and lack of appropriate binding
448 reagents.^{35,36} Analytic considerations may also be relevant to the performance of urinary p75^{ECD},
449 which has not yet achieved the same degree of analytic validation as NfL assays.³⁷

450
451 The design of this study has both strengths and weaknesses. As an observational study rather
452 than a clinical trial, a limitation is that the intervals between study visits were wide (and
453 variable), requiring us to window study visits around defined time points for the repeated-
454 measures analyses (see eTable 8). It is for this reason that we used observed times in a random
455 slopes analyses to estimate sample size savings from incorporation of various potential
456 prognostic biomarkers, despite the FDA's preference for a repeated-measures approach for
457 clinical trials where study visit windows are typically more rigidly controlled. Of note, many ALS
458 clinical trials have historically used this approach³⁸⁻⁴⁰. Moreover, the estimates themselves
459 depend on the duration of follow-up available at the time of analysis and would likely differ over
460 shorter or longer intervals. In addition, due to premature study closure (for administrative
461 reasons between funding cycles) and some attrition, follow up data at 3-, 6-, and 12-month were
462 available for only 85%, 80% and 52% of participants, respectively – resulting in less precise
463 estimates of ALSFRS-R values beyond 6 months. Vital status after a participant's last visit was
464 ascertained based on clinic notes at some sites, with potentially more complete data collection
465 on deaths; this leads to downward bias in estimates of absolute survival percentages but is
466 unlikely to bias estimates of prognostic value. Strengths of this study include the *a priori*
467 selection of a trial-like population, the rigorous attention to the quality of phenotypic data, and

468 the multimodal analysis of putative prognostic biomarkers. Of note, our claims of prognostic
469 utility do not imply any assumption of a causal relationship between a given prognostic and
470 progression rate or survival.

471
472 We also acknowledge the limitations of the ALSFRS-R as an outcome measure in clinical trials,
473 notably the fact that it is not uni-dimensional (meaning that items on the scale measure domains
474 other than functional status)⁴¹; that a one-point change can represent a variable amount of
475 functional change depending on the question and the item⁴², providing a rationale for reporting
476 the domain specific sub-scores of the ALSFRS-R⁴³; and that the decline in ALSFRS-R is not
477 linear across the entire course of disease⁴⁴. Notwithstanding these considerations, the
478 ALSFRS-R is typically linear during the follow-up period encompassed by clinical trials⁴⁵, and
479 remains the principal functional outcome measure used in ALS clinical trials⁴⁶.

480
481 While the longitudinal trajectory of a subset of the biomarkers was not the major focus of this
482 investigation, we have observed subtle increases in NfL and pNfH over time (in contrast to the
483 conventional wisdom that these are largely stable^{8,47-50}). Also noteworthy is the marked
484 increase and relatively consistent trajectory of urinary p75^{ECD} (compared to NfL and pNfH),
485 suggesting that urinary p75^{ECD} might have value as a response or monitoring biomarker.

486
487 It should be acknowledged that our evaluation of changes in biomarkers over time—and of the
488 prognostic value of these biomarkers—has been conducted at a population (or group) level.
489 While statistically robust, conclusions from a population cannot necessarily be extrapolated to
490 individual patients. NfL and other biomarkers considered in our analyses, therefore, remain
491 largely research tools, with more limited (and speculative) value in the clinic setting when
492 applied to individuals.

493
494 While confirmatory studies with larger sample sizes would add confidence to our conclusions,
495 the results of this study are nevertheless immediately relevant to all ongoing and future ALS
496 trials, even in the absence of formal qualification through regulatory agencies such as the
497 FDA.⁵¹ Our findings are especially relevant to trials with 6-month treatment duration, the period
498 for which we have more complete data. First, baseline NfL should be incorporated into the
499 analysis plan for all clinical trials as a prognostic biomarker, whether functional decline or
500 survival is used as the primary outcome. Second, how one incorporates baseline NfL into trial
501 design – either as an eligibility criterion or as a stratification factor – depends on the purpose.

502 For example, if the goal is to enrich the trial population for either faster or slower progressing
503 patients, or to stratify randomisation based on anticipated rate of disease progression, then NfL
504 levels above or below a defined threshold might be used. Our data suggest serum NfL
505 thresholds of <40pg/mL for slow progressors and >100pg/mL for fast progressors. Between 40-
506 100pg/ml, given the steep relationship between NfL increase and faster future rate of ALSFRS-
507 R decline, multiple NfL strata may be required for randomisation (as permitted by study sample
508 size), in order to adequately control for heterogeneity of predicted disease progression rate.
509 (Importantly, the same threshold may not hold for predicting future survival.) Third, in a
510 hypothetical clinical trial with ALSFRS-R slope as the outcome, except for urinary p75^{ECD}, other
511 putative prognostic biomarkers yield very little in the way of sample size saving beyond those
512 conferred by the combination of established clinical predictor(s) and NfL. While incorporation of
513 plasma miR-181ab in such a model does not improve prediction of future rates of ALSFRS-R
514 decline or yield additional sample size savings, it may have some value in predicting survival.
515
516 This study exemplifies the critical importance of a multivariate approach to evaluating new
517 prognostic markers and highlights the necessity for novel markers to demonstrate value added
518 to existing predictors. Moreover, the implication of our finding that clinical predictors
519 (encapsulated, for example, by the ENCALS score) and blood-based measurement of NfL are
520 strong predictors of disease progression, is that both should be incorporated into all ongoing
521 and future Phase 2 and Phase 3 ALS trials. Moreover, the dual use of NfL as a prognostic *and*
522 response biomarker will aid interpretation of Phase 2 trial results and facilitate go/no-go
523 decisions about advancing experimental agents to Phase 3. Collectively, these modifications to
524 ALS trial design and analysis should accelerate the pace of ALS therapy development.
525
526

527 **Contributors**

528 MB: Study concept/design, study oversight, major role in acquisition of data,
529 analysis/interpretation of data, access to and verification of underlying data, and
530 drafting/revising the manuscript for content.

531 EAM: Analysis/interpretation of data, access to and verification of underlying data, and
532 drafting/revising the manuscript for content.

533 AM: Study concept/design, major role in acquisition of data, and drafting/revising the
534 manuscript for content.

535 MLR: Study concept/design, major role in acquisition of data, and drafting/revising the
536 manuscript for content.

537 EH: Major role in acquisition of data and drafting/revising the manuscript for content.

538 VL: Major role in acquisition of data.

539 DR: Major role in acquisition of data.

540 IM: Major role in acquisition of data and drafting/revising the manuscript for content.

541 YC: Major role in acquisition of data.

542 VG: Major role in acquisition of data.

543 JS: Major role in acquisition of data.

544 JH: Major role in acquisition of data.

545 RR: Major role in acquisition of data and editing the manuscript for content.

546 CAM: Major role in generation of summary cognitive/behavioural data.

547 LP: Study concept/design and editing the manuscript for content.

548 CM: Major role in acquisition of data and editing the manuscript for content.

549 JW: Study concept/design, study oversight, major role in acquisition of data,
550 analysis/interpretation of data, access to and verification of underlying data, and
551 drafting/revising the manuscript for content.

552 All authors have read and approved the final version of the manuscript.

553 CReATe Consortium PGB Investigators contributed to data collection.

554

555 **Data Sharing Statement**

556 Following publication, de-identified participant data and a data dictionary defining each field in
557 the dataset, will be made available following request to the corresponding authors and upon
558 execution of a data access agreement. Additional study related documents are not available.

559 **Declaration of Interests**

560 MB reports grants from the NIH (U01NS107027, U54NS092091) and the ALS Association (16-
561 TACL-242) in support of this work. He is also an unpaid member of the Board of Trustees
562 for the ALS Association. He has served as a consultant to Alector, Alexion, Annexon,
563 Arrowhead, Biogen, Cartesian, Denali, Eli Lilly, Horizon, Immunovant, Novartis, Roche,
564 Sanofi, Takeda, UCB, and UniQure.

565 EAM reports grants from the NIH (U01NS107027, U54NS092091). He also serves as a
566 consultant to Annexon, Biogen, Bial Biotech, Cortexyme, Chase Therapeutics, Enterin, nQ
567 Medical, Partner Therapeutics, Stoparkinson Healthcare, and UCB. He has served on
568 DSMBs for NeuroSense Therapeutics, Novartis, and Sanofi.

569 AM reports grants from the NIH (U01NS107027). He has also provided consulting services to
570 Roche, Pfizer, and Accure Therapeutics.

571 MLR reports support from grants from the NIH (U01NS107027, U54NS092091) and FightMND.

572 EH has nothing to declare.

573 VL has nothing to declare.

574 DR has nothing to declare.

575 SS has nothing to declare.

576 IM has nothing to declare.

577 YC has nothing to declare.

578 VG currently is an employee of Biohaven Pharmaceutical Inc.

579 JS receives research funding from the NIH< MDA, FSHD Society, Friends of FSH Research,
580 and FSHD Canada. He also serves as a consultant or on scientific advisory boards for
581 Avidity, Fulcrum, Dyne, Armatus, Epic Bio, Roche, Lupin, and Entrada

582 JH has nothing to declare.

583 RR reports grants from the NIH (U54NS092091) in support of this work. She is also an unpaid
584 member of the Medical Advisory Board of the Association for Frontotemporal Dementias
585 (AFTD) and a paid member of the Scientific Advisory Board of the Kissick Family
586 Foundation FTD Grant Program

587 CAM reports funding from the ALS Association and the NIH (U54NS092091).

588 LP reports support from the Mayo Clinic Foundation and grants from the National Institute on
589 Aging (5P30AG0062677, U19AG063911) the National Institute of Neurological Disorders
590 and Stroke (U54NS123743, R35NS097273, P01NS084974) and Target ALS Foundation.

591 CM reports grants from the NIH (AG066597, AG076411, AG066152, AG072979, NS109260,
592 NS092091), Department of Defense, and support from the Penn Institute on Aging,
593 Decrane Family PPA Fund, and Newhouse Fund.2

594 JW reports funding from the NIH (U01NS107027, U54NS092091) and the ALS Association (16-
595 TACL-242) in support of this work.

596
597 The CReATe Consortium (U54NS092091) is part of the NIH Rare Diseases Clinical Research
598 Network (RDCRN), an initiative of the Office of Rare Diseases Research (ORDR), NCATS. This
599 Consortium is funded through a collaboration between NCATS and the NINDS. This work was
600 also supported by a Clinical Trial Readiness grant (U01NS107027) from NINDS and by a grant
601 from the ALS Association to support the CReATe Biorepository (grant ID 16-TACL-242).

602

603 **Acknowledgements**

604 The authors thank participants in the CReATe Consortium's Phenotype-Genotype-Biomarker (PGB1)
605 study; research staff at each clinical site; and the CReATe Consortium project management and data
606 management teams, genomics sub-core, and biorepository. The authors also thank members of the
607 University of Miami Laboratory for Clinical and Biological Studies for assistance with clinical chemistry
608 assays.

609

610

611

612 References

- 613
- 614 1. Benatar M, Boylan K, Jeromin A, et al. ALS biomarkers for therapy development: State of the field
615 and future directions. *Muscle & nerve* 2016; **53**(2): 169-82.
- 616 2. Witzel S, Frauhammer F, Steinacker P, et al. Neurofilament light and heterogeneity of disease
617 progression in amyotrophic lateral sclerosis: development and validation of a prediction model to
618 improve interventional trials. *Transl Neurodegener* 2021; **10**(1): 31.
- 619 3. Westeneng HJ, Debray TPA, Visser AE, et al. Prognosis for patients with amyotrophic lateral
620 sclerosis: development and validation of a personalised prediction model. *Lancet Neurol* 2018;
621 **17**(5): 423-33.
- 622 4. Benatar M, Zhang L, Wang L, et al. Validation of serum neurofilaments as prognostic and potential
623 pharmacodynamic biomarkers for ALS. *Neurology* 2020; **95**(1): e59-e69.
- 624 5. Miller TM, Cudkovicz ME, Genge A, et al. Trial of Antisense Oligonucleotide Tofersen for SOD1 ALS.
625 *The New England journal of medicine* 2022; **387**(12): 1099-110.
- 626 6. Benatar M, Wu J, Turner MR. Neurofilament light chain in drug development for amyotrophic
627 lateral sclerosis: a critical appraisal. *Brain : a journal of neurology* 2022.
- 628 7. Huang F, Zhu Y, Hsiao-Nakamoto J, et al. Longitudinal biomarkers in amyotrophic lateral sclerosis.
629 *Annals of clinical and translational neurology* 2020; **7**(7): 1103-16.
- 630 8. Thompson AG, Gray E, Verber N, et al. Multicentre appraisal of amyotrophic lateral sclerosis
631 biofluid biomarkers shows primacy of blood neurofilament light chain. *Brain Commun* 2022; **4**(1):
632 fcac029.
- 633 9. Boylan KB, Glass JD, Crook JE, et al. Phosphorylated neurofilament heavy subunit (pNF-H) in
634 peripheral blood and CSF as a potential prognostic biomarker in amyotrophic lateral sclerosis. *J*
635 *Neurol Neurosurg Psychiatry* 2012.
- 636 10. Shephard S, Wu J, Cardoso M, et al. Urinary p75 extracellular domain; A biomarker for
637 prognosis, progression and pharmacodynamic effect in ALS. *Neurology* 2017; **88**(12): 1137-43.
- 638 11. Magen I, Yacovzada NS, Yanowski E, et al. Circulating miR-181 is a prognostic biomarker for
639 amyotrophic lateral sclerosis. *Nature neuroscience* 2021; **24**(11): 1534-41.
- 640 12. Keizman D, Ish-Shalom M, Berliner S, et al. Low uric acid levels in serum of patients with ALS:
641 further evidence for oxidative stress? *Journal of the neurological sciences* 2009; **285**(1-2): 95-9.
- 642 13. Ikeda K, Hirayama T, Takazawa T, Kawabe K, Iwasaki Y. Relationships between disease progression
643 and serum levels of lipid, urate, creatinine and ferritin in Japanese patients with amyotrophic
644 lateral sclerosis: a cross-sectional study. *Intern Med* 2012; **51**(12): 1501-8.
- 645 14. Paganoni S, Zhang M, Quiroz Zarate A, et al. Uric acid levels predict survival in men with
646 amyotrophic lateral sclerosis. *Journal of neurology* 2012; **259**(9): 1923-8.
- 647 15. Zheng Z, Guo X, Wei Q, et al. Serum uric acid level is associated with the prevalence but not with
648 survival of amyotrophic lateral sclerosis in a Chinese population. *Metab Brain Dis* 2014; **29**(3): 771-
649 5.
- 650 16. Chio A, Calvo A, Bovio G, et al. Amyotrophic lateral sclerosis outcome measures and the role of
651 albumin and creatinine: a population-based study. *JAMA neurology* 2014; **71**(9): 1134-42.
- 652 17. Mandrioli J, Rosi E, Fini N, et al. Changes in routine laboratory tests and survival in amyotrophic
653 lateral sclerosis. *Neurol Sci* 2017; **38**(12): 2177-82.
- 654 18. O'Reilly EJ, Liu D, Johns DR, et al. Serum urate at trial entry and ALS progression in EMPOWER.
655 *Amyotroph Lateral Scler Frontotemporal Degener* 2017; **18**(1-2): 120-5.
- 656 19. Paganoni S, Nicholson K, Chan J, et al. Urate levels predict survival in amyotrophic lateral sclerosis:
657 Analysis of the expanded Pooled Resource Open-Access ALS clinical trials database. *Muscle &*
658 *nerve* 2018; **57**(3): 430-4.

- 659 20. Kuffner R, Zach N, Norel R, et al. Crowdsourced analysis of clinical trial data to predict amyotrophic
660 lateral sclerosis progression. *Nature biotechnology* 2015; **33**(1): 51-7.
- 661 21. Paillisse C, Lacomblez L, Dib M, Bensimon G, Garcia-Acosta S, Meininger V. Prognostic factors for
662 survival in amyotrophic lateral sclerosis patients treated with riluzole. *Amyotroph Lateral Scler*
663 *Other Motor Neuron Disord* 2005; **6**(1): 37-44.
- 664 22. Lunetta C, Lizio A, Maestri E, et al. Serum C-Reactive Protein as a Prognostic Biomarker in
665 Amyotrophic Lateral Sclerosis. *JAMA neurology* 2017; **74**(6): 660-7.
- 666 23. Nagel G, Peter RS, Rosenbohm A, et al. Adipokines, C-reactive protein and Amyotrophic Lateral
667 Sclerosis - results from a population- based ALS registry in Germany. *Sci Rep* 2017; **7**(1): 4374.
- 668 24. Cedarbaum JM, Stambler N, Malta E, et al. The ALSFRS-R: a revised ALS functional rating scale that
669 incorporates assessments of respiratory function. BDNF ALS Study Group (Phase III). *Journal of the*
670 *neurological sciences* 1999; **169**(1-2): 13-21.
- 671 25. Kimura F, Fujimura C, Ishida S, et al. Progression rate of ALSFRS-R at time of diagnosis predicts
672 survival time in ALS. *Neurology* 2006; **66**(2): 265-7.
- 673 26. McMillan CT, Wu J, Rascovsky K, et al. Defining cognitive impairment in amyotrophic lateral
674 sclerosis: an evaluation of empirical approaches. *Amyotroph Lateral Scler Frontotemporal Degener*
675 2022; **23**(7-8): 517-26.
- 676 27. Rogers ML, Atmosukarto I, Berhanu DA, Matusica D, Macardle P, Rush RA. Functional monoclonal
677 antibodies to p75 neurotrophin receptor raised in knockout mice. *Journal of neuroscience methods*
678 2006; **158**(1): 109-20.
- 679 28. Thompson SJ, Schatteman GC, Gown AM, Bothwell M. A monoclonal antibody against nerve
680 growth factor receptor. Immunohistochemical analysis of normal and neoplastic human tissue. *Am*
681 *J Clin Pathol* 1989; **92**(4): 415-23.
- 682 29. Shephard SR, Karnaros V, Benyamin B, et al. Urinary neopterin: A novel biomarker of disease
683 progression in amyotrophic lateral sclerosis. *Eur J Neurol* 2022; **29**(4): 990-9.
- 684 30. Mikheev MI, Lowry LK. WHO global project on biological monitoring of chemical exposure at the
685 workplace. *Int Arch Occup Environ Health* 1996; **68**(6): 387-8.
- 686 31. DeJesus-Hernandez M, Mackenzie IR, Boeve BF, et al. Expanded GGGGCC Hexanucleotide Repeat in
687 Noncoding Region of C9ORF72 Causes Chromosome 9p-Linked FTD and ALS. *Neuron* 2011.
- 688 32. Strong MJ, Abrahams S, Goldstein LH, et al. Amyotrophic lateral sclerosis - frontotemporal
689 spectrum disorder (ALS-FTSD): Revised diagnostic criteria. *Amyotroph Lateral Scler Frontotemporal*
690 *Degener* 2017; **18**(3-4): 153-74.
- 691 33. McHutchison CA, Wu J, McMillan CT, et al. Temporal course of cognitive and behavioural changes
692 in motor neuron diseases. *J Neurol Neurosurg Psychiatry* 2023.
- 693 34. Greenland S. Dose-response and trend analysis in epidemiology: alternatives to categorical
694 analysis. *Epidemiology* 1995; **6**(4): 356-65.
- 695 35. Halbgebauer S, Steinacker P, Verde F, et al. Comparison of CSF and serum neurofilament light and
696 heavy chain as differential diagnostic biomarkers for ALS. *J Neurol Neurosurg Psychiatry* 2022;
697 **93**(1): 68-74.
- 698 36. Sturmey E, Malaspina A. Blood biomarkers in ALS: challenges, applications and novel frontiers.
699 *Acta Neurol Scand* 2022; **146**(4): 375-88.
- 700 37. Rogers ML, Schultz DW, Karnaros V, Shephard SR. Urinary biomarkers for amyotrophic lateral
701 sclerosis: candidates, opportunities and considerations. *Brain Commun* 2023; **5**(6): fcad287.
- 702 38. Cudkovicz ME, Titus S, Kearney M, et al. Safety and efficacy of ceftriaxone for amyotrophic lateral
703 sclerosis: a multi-stage, randomised, double-blind, placebo-controlled trial. *Lancet Neurol* 2014;
704 **13**(11): 1083-91.

- 705 39. Vucic S, Menon P, Huynh W, et al. Efficacy and safety of CNM-Au8 in amyotrophic lateral sclerosis
706 (RESCUE-ALS study): a phase 2, randomised, double-blind, placebo-controlled trial and open label
707 extension. *EClinicalMedicine* 2023; **60**: 102036.
- 708 40. Schoenfeld DA, Finkelstein DM, Macklin E, et al. Design and analysis of a clinical trial using previous
709 trials as historical control. *Clin Trials* 2019; **16**(5): 531-8.
- 710 41. van Eijk RPA, de Jongh AD, Nikolakopoulos S, et al. An old friend who has overstayed their
711 welcome: the ALSFRS-R total score as primary endpoint for ALS clinical trials. *Amyotroph Lateral*
712 *Scler Frontotemporal Degener* 2021; **22**(3-4): 300-7.
- 713 42. Fournier CN. Considerations for Amyotrophic Lateral Sclerosis (ALS) Clinical Trial Design.
714 *Neurotherapeutics* 2022; **19**(4): 1180-92.
- 715 43. Rooney J, Burke T, Vajda A, Heverin M, Hardiman O. What does the ALSFRS-R really measure? A
716 longitudinal and survival analysis of functional dimension subscores in amyotrophic lateral
717 sclerosis. *J Neurol Neurosurg Psychiatry* 2017; **88**(5): 381-5.
- 718 44. Gordon PH, Cheng B, Salachas F, et al. Progression in ALS is not linear but is curvilinear. *Journal of*
719 *neurology* 2010; **257**(10): 1713-7.
- 720 45. Proudfoot M, Jones A, Talbot K, Al-Chalabi A, Turner MR. The ALSFRS as an outcome measure in
721 therapeutic trials and its relationship to symptom onset. *Amyotroph Lateral Scler Frontotemporal*
722 *Degener* 2016; **17**(5-6): 414-25.
- 723 46. Genge A, Cedarbaum JM, Shefner J, et al. The ALSFRS-R Summit: a global call to action on the use
724 of the ALSFRS-R in ALS clinical trials. *Amyotroph Lateral Scler Frontotemporal Degener* 2024; **25**(3-
725 4): 382-7.
- 726 47. Lu CH, Macdonald-Wallis C, Gray E, et al. Neurofilament light chain: A prognostic biomarker in
727 amyotrophic lateral sclerosis. *Neurology* 2015; **84**(22): 2247-57.
- 728 48. Steinacker P, Huss A, Mayer B, et al. Diagnostic and prognostic significance of neurofilament light
729 chain NF-L, but not progranulin and S100B, in the course of amyotrophic lateral sclerosis: Data
730 from the German MND-net. *Amyotroph Lateral Scler Frontotemporal Degener* 2017; **18**(1-2): 112-
731 9.
- 732 49. Gille B, De Schaepdryver M, Goossens J, et al. Serum neurofilament light chain levels as a marker
733 of upper motor neuron degeneration in patients with Amyotrophic Lateral Sclerosis. *Neuropathol*
734 *Appl Neurobiol* 2019; **45**(3): 291-304.
- 735 50. Verde F, Steinacker P, Weishaupt JH, et al. Neurofilament light chain in serum for the diagnosis of
736 amyotrophic lateral sclerosis. *J Neurol Neurosurg Psychiatry* 2019; **90**(2): 157-64.
- 737 51. Benatar M, Ostrow LW, Lewcock JW, et al. Biomarker Qualification for Neurofilament Light Chain in
738 Amyotrophic Lateral Sclerosis: Theory and Practice. *Annals of neurology* 2024; **95**(2): 211-6.
- 739
740
741

742 **Figure Legends**

743

744 **Figure 1. ALSFRS-R Slope and its Relationship to Baseline NfL**

745 **(a)** Random slopes model of ALSFRS-R over time, with errors bars showing 95% confidence
746 intervals (CI). Faint grey dotted line illustrates the linear estimate of change in ALSFRS-R over
747 time. **(b)** Relationship between baseline serum NfL (measured in duplicate) and future rate of
748 progression of the ALSFRS-R (Spearman correlation coefficient = -0.57, 95% CI -0.66 to -0.47,
749 $p < 0.0001$) among $n = 203$ study participants. The straight orange line shows the linear
750 prediction. The bent blue line represents a partial-linear spline with knots chosen post-hoc at
751 40 and 100 pg/mL. The smooth green curve is a smoothing spline through the empirical Bayes
752 slope estimates.

753

754 **Figure 2. Longitudinal Biomarker Trajectories**

755 Longitudinal trajectories of **(a)** serum NfL; **(b)** serum pNfH; and **(c)** urinary $p75^{ECD}$. Y-axis
756 shows percent change in each biomarker compared to baseline, plotted on a log scale. The
757 faint grey dotted line illustrates the linear estimate of biomarker change over time. Error bars
758 represent 95% confidence intervals (CI), widened at later time points due to participant attrition
759 over time and fewer biomarker data available. NfL and pNfH were measured in duplicate;
760 $p75^{ECD}$ quantified with a median of 3 replicates. Single NfL and pNfH values from the 18-month
761 visit of a single participant have been excluded (see footnote to Table 2 for detailed
762 explanation).

763

764 **Figure 3. Kaplan-Meier Survival Curves**

765 Permanent assisted ventilation (PAV)- and tracheostomy-free survival for **(a)** the ENCALS
766 predictor score, divided into quartiles; **(b)** Δ FRS, divided into quartiles; **(c)** baseline serum NfL,
767 divided into quartiles; and **(d)** baseline plasma miR-181ab dichotomised at the median value of
768 24,590 UMI. The range of values for each clinical or biological marker within a defined quartile,
769 as well as the number of observations at each time point, are shown below each KM plot.
770 Shading represents pointwise log-log confidence intervals.

771

772

773

774 **Tables**

775

776 **Table 1a. Baseline demographic and key clinical features**

777

Characteristic		Total N=203
Sex	Male	112 (55.2%)
	Female	91 (44.8%)
Race	White	179 (88.2%)
	Black	15 (7.4%)
	Asian	4 (2.0%)
	Other	5 (2.5%)
Ethnicity	Hispanic/Latino	36 (17.7%)
	Non-Hispanic/Latino	167 (82.3%)
Gene with a pathogenic variant	<i>C9orf72</i>	20 (9.9%)
	<i>SOD1</i>	3 (1.5%)
	<i>TARDBP</i>	1 (0.5%)
	[Unknown] ²	179 (88.2%)
Age at onset, years	Mean ± SD (Range)	57.1 ± 12.0 (15-82)
Bulbar symptoms at onset	No	147 (72.4%)
	Yes	56 (27.6%)
Diagnostic delay, months	Median (Q1-Q3)	8.2 (5.2-13.8)
Time from symptom onset to baseline, months	Median (Q1-Q3)	14.4 (10.5-22.5)
Baseline ΔFRS, points/month	Median (Q1-Q3)	0.60 (0.4-0.9)
Baseline age, years	Mean ± SD (Range)	58.5 ± 12.1 (17-83)
Baseline EI Escorial category	Clinically definite ALS	45 (22.2%)
	Clinically probable ALS	95 (46.8%)
	Other	63 (31.0%)
Baseline ALSFRS-R total score	Mean ± SD (Range)	37.9 ± 5.7 (15-48)
Baseline SVC, %predicted	Mean ± SD (Range)	85.3 ± 17.2 (52.0-135.5)
Baseline ECAS total score ¹	Mean ± SD (Range)	110.2 ± 12.4 (44-130)
Baseline ECAS ALS-specific score ¹	Mean ± SD (Range)	81.8 ± 10.3 (35-97)
Baseline ECAS ALS non-specific score ¹	Mean ± SD (Range)	28.4 ± 3.7 (9-35)
Baseline cognitive impairment, by ECAS	No	137 (87.8%)
	Yes	19 (12.2%)
	[n/a] ³	47 (--)
Baseline behavioural impairment, by ECAS	No	95 (84.8%)
	Yes	17 (15.2%)
	[n/a] ⁴	91 (--)
Survival duration from baseline, months	Median (Q1-Q3)	30.1 (17.4-47.7)
PAV, tracheostomy, or death occurrence	No	110 (54.2%)
	Yes	93 (45.8%)
Number of sample collections	2	48 (23.6%)
	3	56 (27.6%)
	4	47 (23.2%)
	5	52 (25.6%)

778 ¹ Among English speakers (n=171)

779 ² No pathogenic variant identified (by *C9orf72* testing and whole genome sequencing) in known disease-causing genes.

780 ³ Not available, because a non-English version of ECAS was completed or if there was insufficient information to determine impairment status.

781 ⁴ Not available, because a non-English version of ECAS was completed, caregiver did not complete ECAS, or if there was insufficient information to determine impairment status.

782

783

784

785

786 SD = Standard deviation. Q1 = 1st quartile. Q3 = 3rd quartile.
787 ECAS = Edinburgh Cognitive and Behavioural ALS Screen.
788 SVC = Slow vital capacity. PAV = Permanent assisted ventilation.
789
790
791

792 **Table 1b. Baseline biomarker data**
793

Biomarker	N	Mean \pm SD	Median (Q1, Q3)	Range
Serum NfL (pg/mL)	203	73.9 \pm 47.0	67.9 (37.9, 92.5)	9.1 – 214
Serum pNfH (pg/mL)	203	598 \pm 718	267 (110, 924)	3.4 – 4,177
Serum NfL/pNfH ratio	203	0.52 \pm 1.56	0.18 (0.09, 0.50)	0.020 – 20.9
Urinary p75 ^{ECD} (ng/mg creatinine)	160 ¹	5.54 \pm 2.42	5.05 (3.93, 6.44)	1.53 – 16.1
Serum uric acid (mg/dL)	203	5.19 \pm 1.31	5.00 (4.20, 6.20)	2.60 – 8.90
Serum creatinine (mg/dL)	203	0.78 \pm 0.20	0.77 (0.66, 0.90)	0.29 – 1.59
Serum albumin (g/dL)	203	4.55 \pm 0.34	4.50 (4.30, 4.80)	3.60 – 5.80
Serum CRP (mg/dL)	203	0.27 \pm 0.35	0.10 (0.10, 0.50)	0.10 – 2.30
Plasma miR-181a (UMI)	201	451 \pm 208	418 (312, 552)	124 – 1,699
Plasma miR-181b (UMI)	201	66.2 \pm 31.4	61.2 (44.8, 79.7)	13.8 – 263
Plasma miR-181ab (UMI ²)	201	34,663 \pm 39,372	24,590 (13,638, 42,836)	3,148 – 447,480

794 UMI = unique molecular identifier

795
796 ¹ Urinary p75^{ECD} only available from a subset of study participants.

797
798
799
800
801
802
803
804
805
806

Table 2. Longitudinal biomarker trajectories

Biomarker	Increase per month, relative to baseline		
	Mean	(95% CI)	P-value
Serum NfL (pg/mL) ¹	0.98%	(0.57%, 1.38%)	<0.0001
Serum pNfH (pg/mL) ¹	0.45%	(-0.12%, 1.03%)	0.12
Serum NfL/pNfH ratio	0.44%	(-0.09%, 0.97%)	0.10
Urinary p75 ^{ECD} (ng/mg creatinine)	2.59%	(2.01%, 3.17%)	<0.0001

807 Values are unadjusted for core clinical covariates

808
809 ¹ One substantial outlier, from the 18-month visit (i.e. visit 5) of a participant, was excluded.

810

Table 3. Prognostic markers of survival

Prognostic Marker (in quartiles or binary)	Unadjusted Analysis*					Adjusted Analysis*			
	Estimated median survival (95% CI) in months ¹ , by marker quartile					Covariates included: Core clinical predictors ²		Covariate included: ENCALS predictor score ³	
	Q1 / No	Q2	Q3	Q4 / Yes	p-value	HR (95% CI) [Q4 vs Q1] ⁴	p-value	HR (95% CI) [Q4 vs Q1] ⁵	p-value
Sex, male	25 (22-37)	--	--	31 (26-46)	0.62	1.13 (0.7-1.8)	0.61	0.98 (0.6-1.5)	0.91
Age at onset, years	47 (31-48)	25 (21-37)	24 (17-37)	22 (16-34)	0.023	1.33 (0.3-6.2)	0.28	1.34 (0.7-2.6)	0.59
Bulbar symptoms at onset	33 (30-46)	--	--	22 (17-27)	0.039	N/A		1.31 (0.8-2.0)	0.25
Diagnostic delay	30 (22-37)	27 (20-48)	27 (22-ne)	56 (21-ne)	0.096	0.65 (0.1 - 3.1)	0.73	1.66 (0.7-3.7)	0.43
Baseline ΔFRS	47 (34-ne)	35 (22-56)	30 (22-43)	17 (14-27)	<0.0001 ¹³	3.64 (1.3-10.5)	0.11	1.62 (0.7-3.7)	0.39
Baseline age	46 (30-48)	23 (19-37)	25 (19-43)	30 (17-34)	0.073	0.46 (0.1-2.2)	0.10	1.21 (0.6-2.3)	0.23
Baseline ALSFRS-R	22 (16-26)	24 (21-32)	48 (31-ne)	43 (31-48)	0.0010 ¹³	0.55 (0.3-1.1)	0.03	0.61 (0.3-1.1)	0.04
Baseline SVC %predicted	20 (15-27)	31 (23-47)	34 (24-ne)	47 (27-ne)	0.0046	0.49 (0.3-0.9)	0.10	0.64 (0.3-1.2)	0.58
Baseline ECAS total ⁶	31 (15-56)	30 (22-47)	31 (19-48)	48 (24-ne)	0.54	0.99 (0.5-2.1)	0.78	0.77 (0.4-1.6)	0.75
Baseline ECAS ALS-specific ⁶	37 (18-ne)	30 (20-47)	23 (17-49)	48 (26-ne)	0.14	1.12 (0.5-2.6)	0.12	0.88 (0.4-2.0)	0.17
Baseline ECAS ALS non-specific ⁶	25 (14-37)	47 (26-48)	30 (19-ne)	31 (23-48)	0.37	0.68 (0.3-1.4)	0.73	0.65 (0.3-1.3)	0.66
Baseline cognitive impairment ⁶	30 (25-46)	--	--	37 (13-ne)	0.99	0.70 (0.3-1.5)	0.41	0.84 (0.3-1.7)	0.67
Baseline behavioural impairment ⁶	34 (25-47)	--	--	18 (8-ne)	0.48	1.06 (0.4-2.4)	0.90	1.67 (0.7-3.6)	0.22
Baseline ENCALS predictor score	48 (39-ne)	35 (26-ne)	24 (20-32)	17 (13-25)	<0.0001 ¹³	4.55 (1.5 -14.7)	0.054	1.61 (0.3-7.4)	0.87
Baseline serum NfL	49 (46-ne)	30 (23-35)	26 (17-39)	17 (13-22)	<0.0001 ¹³	7.71 (3.7 -17.1)	<0.0001 ¹³	7.34 (3.7-15.8)	<0.0001 ¹³
Baseline serum pNfH	43 (30-ne)	23 (17-37)	25 (23-46)	26 (19-47)	0.18	1.74 (1.0-3.2)	0.28	1.68 (1.0-3.0)	0.36
Baseline urinary p75 ^{ECD}	34 (24-46)	31 (21-ne)	22 (14-ne)	30 (19-48)	0.77	0.92 (0.4-1.9)	0.94	0.65 (0.3-1.3)	0.57
Baseline serum uric acid	25 (21-37)	31 (15-46)	30 (23-34)	47 (25-56)	0.25	0.69 (0.4-1.3)	0.38	0.58 (0.3-1.1)	0.22
Baseline serum creatinine	31 (21-46)	24 (19-48)	31 (22-ne)	30 (23-47)	0.99	0.87 (0.5-1.6)	0.89	0.95 (0.5-1.7)	0.97
Baseline serum albumin	25 (20-35)	23 (19-52)	32 (22-47)	34 (27-47)	0.72	0.95 (0.5-1.8)	0.99	0.96 (0.5-1.8)	0.96
Baseline serum CRP	30 (24-39)		26 (9-ne)	30 (22-47)	0.85	1.07 (0.6-1.8)	0.96	1.08 (0.6-1.7)	0.95
Baseline plasma miR-181ab	35 (30-ne)	34 (24-52)	26 (20-47)	22 (17-30)	0.021	1.90 (1.0-3.6)	0.16	1.82 (1.0-3.3)	0.096
Baseline miR-181ab > 39,300 UMI ⁷	33 (26-48)	--	--	23 (17-32)	0.0062	1.55 (0.9-2.5)	0.075	1.55 (1.0-2.4)	0.050
Baseline miR-181ab > 24,590 UMI ⁸	35 (30-48)	--	--	23 (20-32)	0.016	1.65 (1.1-2.6)	0.030	1.73 (1.1-2.7)	0.014
Baseline NfL+miR181ab poor Px ⁹	37 (30-48)	--	--	17 (15-21)	<0.0001 ¹³	2.69 (1.6-4.4)	0.0001 ¹³	2.61 (1.7-4.1)	<0.0001 ¹³
Baseline NfL+miR181ab poor Px ¹⁰	47 (34-48)	--	--	20 (16-22)	<0.0001 ¹³	3.14 (2.0-5.1)	<0.0001 ¹³	3.19 (2.0-5.0)	<0.0001 ¹³
Baseline NfL median split ¹¹	47 (31-48)	--	--	20 (16-25)	<0.0001 ¹³	2.24 (1.4-3.6)	0.0006 ¹³	2.29 (1.5-3.6)	0.0002 ¹³
Baseline NfL 4-level split ¹²	47 (46-52)	24 (19-31)	32 (14-18)	17 (15-22)	<0.0001 ¹³	4.28 (2.4-8.0)	0.0001 ¹³	4.12 (2.3-7.5)	0.0001 ¹³

*Survival analysis. Q1-Q4 indicate quartiles of continuous predictors, with higher quartiles representing higher values. Yes/No in column headings captures the presence/absence of binary predictors. ne = not estimable.

¹ Without inclusion of covariate or prognostic marker in the model, median survival (95% CI) = 30 (17-48) months.

² Core clinical predictors in survival analyses include bulbar onset, diagnostic delay, Δ FRS, and baseline age.

³ ENCALS predictor score is derived from Δ FRS, bulbar onset, diagnostic delay, age at onset, SVC percent predicted, El Escorial definite ALS, presence of FTD, and presence of a *C9orf72* repeat expansion.

⁴ These HRs compare Q4 to Q1 of each prognostic marker in a model that also adjusts for the core clinical predictors of survival. While the adjusted analyses include diagnostic delay, Δ FRS, and baseline age as linear covariates, the potential additional prognostic value of each of these predictors (see respective rows) is evaluated by contrasting top and bottom quartiles to detect possible non-linear effects.

⁵ These HRs compare Q4 to Q1 of each prognostic marker in a model that also adjusts for the ENCALS score as a linear covariate. The potential additional prognostic value of the ENCALS predictor score (see row) is evaluated by contrasting top and bottom quartiles to detect possible non-linear effects.

⁶ Among English speakers (n=171)

⁷ Threshold of 39,300 UMI in plasma as defined by Magen et al ¹¹

⁸ Median of 24,590 UMI in plasma in the current dataset

⁹ Poor prognosis based on published optimal combination of NfL and miR-181ab, in which a poor prognostic factor is defined as either (NfL > 109.8pg/ml) or (NfL > 59.0pg/ml and miR-181ab > 39,300 UMI) ¹¹.

¹⁰ Poor prognosis based on recalculated combination of NfL and miR-181ab using thresholds obtained from the current dataset; a poor prognostic factor is defined as either (NfL > 80.8 pg/mL) or (NfL > 44.8 pg/mL and miR-181ab > 24,590 UMI).

¹¹ Median serum NfL = 67.9 pg/mL

¹² Serum NfL 4-level split is at the 33rd, 50th, and 67th percentiles (44.8 pg/mL, 67.9 pg/mL, and 80.8 pg/mL, respectively), i.e., tertiles and median, rather than quartiles, to mimic construction of the NfL+miR18ab measure ¹¹.

¹³ p-value remains statistically significant after adjustment for multiplicity. Holm-Bonferroni adjusted p-values are reported in eTable 7.

Table 4. Prognostic markers of functional decline

Prognostic Marker (in quartiles or binary)	Unadjusted Analysis *					Adjusted Analysis *				
	ALSFRS-R slope (points/month): Estimate (SE) ¹				p-value	ALSFRS-R slope (points/month): Estimate (SE) ¹				p-value
	Q1 /No	Q2	Q3	Q4 / Yes		Q1 /No	Q2	Q3	Q4 / Yes	
Sex, male	-0.90 (-1.1, -0.74)	--	--	-0.88 (-1.0, -0.73)	0.80	-0.90 (-1.1, -0.75)	--	--	-0.88 (-1.0, -0.74)	0.83
Age at onset	-0.74 (-.95, -0.53)	-0.90 (-1.1, -0.70)	-1.00 (-1.2, -0.79)	-0.91 (-1.1, -0.67)	0.38	-0.87 (-1.1, -0.66)	-0.91 (-1.10, -0.72)	-0.95 (-1.1, -0.75)	-0.79 (-1.0, -0.56)	0.77
Bulbar symptoms at onset	-0.82 (-.94, -0.70)	--	--	-1.07 (-1.3, -0.87)	0.036	-0.84 (-0.96, -0.72)	--	--	-1.02 (-1.2, -0.82)	0.14
Diagnostic delay	-1.10 (-1.3, -.090)	-0.99 (-1.2, -0.79)	-0.70 (-.92, -0.48)	-0.73 (-.93, -0.52)	0.016	-0.99 (-1.2, -0.78)	-0.93 (-1.10, -0.73)	-0.73 (-0.94, -0.51)	-0.89 (-1.1, -0.66)	0.38
Baseline ΔFRS	-0.72 (-0.91, -0.54)	-0.83 (-1.0, -0.62)	-0.69 (-.89, -0.48)	-1.37 (-1.6, -1.1)	<0.0001 ¹⁰	-0.87 (-1.1, -0.66)	-0.83 (-1.00, -0.62)	-0.66 (-0.86, -0.45)	-1.22 (-1.5, -0.98)	0.0036
Baseline age	-0.76 (-0.97, -0.55)	-0.99 (-1.2, -0.79)	-0.91 (-1.1, -0.69)	-0.89 (-1.1, -0.66)	0.47	-0.88 (-1.1, -0.68)	-0.99 (-1.20, -0.79)	-0.87 (-1.1, -0.66)	-0.80 (-1.0, -0.58)	0.63
Baseline ALSFRS-R	-0.96 (-1.2, -0.75)	-0.92 (-1.1, -0.70)	-0.68 (-.92, -0.45)	-0.93 (-1.1, -0.73)	0.31	-0.88 (-1.1, -0.67)	-0.93 (-1.10, -0.72)	-0.70 (-0.92, -0.47)	-1.00 (-1.2, -0.80)	0.24
Baseline SVC %predicted	-1.08 (-1.3, -0.86)	-0.90 (-1.1, -0.70)	-0.85 (-1.1, -0.64)	-0.70 (-.92, -0.48)	0.12	-0.96 (-1.2, -0.74)	-0.92 (-1.10, -0.72)	-0.91 (-1.1, -0.71)	-0.73 (-0.94, -0.52)	0.44
Baseline ECAS total ²	-0.99 (-1.2, -0.76)	-0.77 (-1.0, -0.53)	-0.79 (-1.0, -0.55)	-0.84 (-1.1, -0.60)	0.54	-0.98 (-1.2, -0.76)	-0.72 (-0.95, -0.49)	-0.80 (-1.0, -0.57)	-0.92 (-1.1, -0.68)	0.38
Baseline ECAS ALS-specific ²	-0.83 (-1.1, -0.60)	-0.84 (-1.1, -0.62)	-0.92 (-1.2, -0.68)	-0.81 (-1.1, -0.55)	0.92	-0.84 (-1.1, -0.61)	-0.81 (-1.00, -0.59)	-0.93 (-1.2, -0.70)	-0.85 (-1.1, -0.60)	0.89
Baseline ECAS ALS non-specific ²	-0.91 (-1.1, -0.67)	-0.70 (-.92, -0.48)	-0.98 (-1.2, -0.75)	-0.80 (-1.1, -0.54)	0.36	-0.87 (-1.1, -0.65)	-0.73 (-0.95, -0.52)	-0.99 (-1.2, -0.77)	-0.82 (-1.1, -0.56)	0.42
Baseline cognitive impairment ²	-0.83 (-0.96, -0.70)	--	--	-0.89 (-1.2, -0.54)	0.73	-0.83 (-0.95, -0.70)	--	--	-0.89 (-1.2, -0.54)	0.75
Baseline behavioural impairment ²	-0.78 (-0.93, -0.63)	--	--	-1.04 (-1.4, -0.66)	0.21	-0.76 (-0.90, -0.61)	--	--	-0.97 (-1.3, -0.61)	0.29
Baseline ENCALs predictor score	-0.57 (-0.76, -0.37)	-0.70 (-.89, -0.51)	-1.02 (-1.2, -0.81)	-1.27 (-1.5, -1.1)	<0.0001 ¹⁰	-0.62 (-0.90, -0.34)	-0.71 (-0.90, -0.51)	-1.00 (-1.2, -0.79)	-1.23 (-1.5, -0.96)	0.021
Baseline serum NFL	-0.41 (-0.58, -0.24)	-0.67 (-.84, -0.50)	-1.10 (-1.3, -0.92)	-1.49 (-1.7, -1.3)	<0.0001 ¹⁰	-0.44 (-0.60, -0.27)	-0.71 (-0.88, -0.54)	-1.08 (-1.3, -0.90)	-1.44 (-1.6, -1.2)	<0.0001 ¹⁰
Baseline serum pNFH	-0.68 (-0.88, -0.48)	-0.96 (-1.2, -0.74)	-0.82 (-1.0, -0.61)	-1.13 (-1.4, -0.91)	0.024	-0.70 (-0.89, -0.51)	-0.91 (-1.10, -0.71)	-0.86 (-1.1, -0.65)	-1.12 (-1.3, -0.91)	0.041
Baseline urinary p75 ^{ECD}	-0.93 (-1.2, -0.70)	-0.75 (-1.0, -0.50)	-1.03 (-1.3, -0.79)	-0.97 (-1.2, -0.73)	0.44	-0.99 (-1.2, -0.77)	-0.76 (-1.00, -0.52)	-0.96 (-1.2, -0.73)	-0.96 (-1.2, -0.73)	0.50
Baseline serum uric acid	-0.96 (-1.2, -0.75)	-0.85 (-1.1, -0.63)	-0.91 (-1.1, -0.70)	-0.82 (-1.0, -0.60)	0.82	-0.98 (-1.2, -0.78)	-0.82 (-1.00, -0.61)	-0.93 (-1.1, -0.73)	-0.81 (-1.0, -0.60)	0.61
Baseline serum creatinine	-0.90 (-1.1, -0.69)	-0.89 (-1.1, -0.67)	-0.80 (-1.0, -0.57)	-0.95 (-1.2, -0.74)	0.81	-0.91 (-1.1, -0.71)	-0.94 (-1.20, -0.73)	-0.76 (-0.98, -0.54)	-0.93 (-1.1, -0.74)	0.61
Baseline serum albumin	-0.82 (-1.0, -0.61)	-0.87 (-1.1, -0.64)	-1.03 (-1.2, -0.85)	-0.71 (-.98, -0.45)	0.23	-0.74 (-0.95, -0.54)	-0.83 (-1.00, -0.62)	-1.09 (-1.3, -0.92)	-0.76 (-1.0, -0.50)	0.039
Baseline serum CRP ³	-0.85 (-0.97, -0.72)		-1.12 (-1.6, -0.66)	-0.97 (-1.2, -0.74)	0.38	-0.84 (-0.96, -0.72)		-1.08 (-1.5, -0.64)	-0.98 (-1.2, -0.77)	0.37
Baseline plasma miR-181ab	-0.71 (-0.92, -0.50)	-0.82 (-1.0, -0.61)	-0.92 (-1.1, -0.70)	-1.11 (-1.3, -0.89)	0.061	-0.71 (-0.91, -0.51)	-0.83 (-1.00, -0.63)	-0.95 (-1.2, -0.74)	-1.07 (-1.3, -0.86)	0.085
Baseline miR-181ab > 39,300 UMI ⁴	-0.80 (-0.93, -0.68)	--	--	-1.09 (-1.3, -0.89)	0.017	-0.82 (-0.94, -0.70)	--	--	-1.06 (-1.3, -0.87)	0.037
Baseline miR-181ab > 24,590 UMI ⁵	-0.76 (-0.91, -0.61)	--	--	-1.01 (-1.2, -0.86)	0.023	-0.77 (-0.91, -0.63)	--	--	-1.01 (-1.2, -0.86)	0.022
Baseline NFL+miR181ab poor Px ⁶	-0.69 (-0.80, -0.57)	--	--	-1.39 (-1.6, -1.2)	<0.0001 ¹⁰	-0.71 (-0.82, -0.60)	--	--	-1.34 (-1.5, -1.1)	<0.0001 ¹⁰
Baseline NFL+miR181ab poor Px ⁷	-0.56 (-0.68, -0.43)	--	--	-1.28 (-1.4, -1.1)	<0.0001 ¹⁰	-0.59 (-0.72, -0.47)	--	--	-1.24 (-1.4, -1.1)	<0.0001 ¹⁰
Baseline NFL median split ⁸	-0.54 (-0.66, -0.41)	--	--	-1.28 (-1.4, -1.1)	<0.0001 ¹⁰	-0.58 (-0.70, -0.45)	--	--	-1.24 (-1.4, -1.1)	<0.0001 ¹⁰
Baseline NFL 4-level split ⁹	-0.44 (-0.59, -0.30)	-0.73 (-.94, -0.52)	-1.05 (0.11)	-1.41 (-1.6, -1.2)	<0.0001 ¹⁰	-0.48 (-0.63, -0.34)	-0.74 (-0.95, -0.53)	-1.05 (-1.3, -0.83)	-1.36 (-1.5, -1.2)	<0.0001 ¹⁰

* Random slopes model. ENCALS predictor score included in adjusted analysis. Q1-Q4 indicate quartiles of continuous predictors, with higher quartiles representing higher values. Yes/No in column headings captures the presence/absence of binary predictors.

¹ Without inclusion of covariate or prognostic marker in the model, ALSFRS-R slope (SE) = -0.89 (0.05) points/month.

² Among English speakers (n=171)

³ More than 50% of observations were below the lower limit of quantification and were imputed at 0.1 mg/dL

⁴ Threshold of 39,300 UMI in plasma as defined by Magen et al ¹¹

⁵ Median of 24,590 UMI in plasma in the current dataset

⁶ Poor prognosis based on published optimal combination of NfL and miR-181ab, in which a poor prognostic factor is defined as either (NfL > 109.8 pg/mL) or (NfL > 59.0 pg/mL and miR-181ab > 39,300 UMI) ¹¹.

⁷ Poor prognosis based on recalculated combination of NfL and miR-181ab using thresholds obtained from the current dataset; a poor prognostic factor is defined as either (NfL > 80.8 pg/mL) or (NfL > 44.8 pg/mL and miR-181ab > 24,590 UMI).

⁸ Median serum NfL = 67.9 pg/mL

⁹ Serum NfL 4-level split is at the 33rd, 50th, and 67th percentiles (44.8 pg/mL, 67.9 pg/mL, and 80.8 pg/mL, respectively), i.e., tertiles and median, rather than quartiles, to mimic construction of the NfL+miR18ab measure ¹¹.

¹⁰ p-value remains statistically significant after adjustment for multiplicity. Holm-Bonferroni adjusted p-values are reported in eTable 7.

Table 5. Estimated total sample size savings in a random slopes model of ALSFRS-R progression that includes the prognostic marker and covariate(s)

Prognostic Marker	Unadjusted	Covariate(s) included			
		Core clinical predictors ¹	ENCALS predictor score ²	Core clinical predictors ¹ + NfL	ENCALS predictor score ² + NfL
ENCALS linear score	-9.0%	-10.4%	--	-33.6%	--
Serum NfL	-30.9%	-33.4%	-33.6%	--	--
Serum pNfH	-4.0%	-13.3%	-12.3%	-33.2%	-33.5%
Urinary p75 ^{ECD}	-7.6%	-13.2%	-16.4%	-37.2%	-37.5%
Serum uric acid	-0.8%	-8.2%	-8.2%	-33.2%	-33.3%
Serum creatinine	1.2%	-8.3%	-7.8%	-33.0%	-33.2%
Serum albumin	1.9%	-8.1%	-7.4%	-33.2%	-33.4%
Serum CRP	-0.3%	-10.3%	-9.3%	-33.5%	-33.4%
Plasma miR-181ab	-2.0%	-9.7%	-10.6%	-34.2%	-35.4%
NfL+miR181ab poor Px ³	-20.7%	-9.9%	-24.8%	-34.5%	-34.1%
NfL+miR181ab poor Px ⁴	-25.1%	-9.3%	-28.9%	-33.8%	-34.9%
NfL median split ⁵	-26.5%	-29.2%	-29.4%	-34.2%	-34.4%
NfL 4-level split ⁶	-31.4%	-33.8%	-33.4%	-34.8%	-34.6%

Values indicate the combined percent sample size reduction when the prognostic identified by a row heading is added to covariates described in column headings, in a hypothetical clinical trial with ALSFRS-R as the outcome measure, assuming the experimental therapeutic has a 30% treatment effect.

¹ Core clinical predictors of functional decline include bulbar onset, diagnostic delay, and Δ FRS.



² ENCALs predictor score is derived from Δ FRS, bulbar onset, diagnostic delay, age at onset, SVC percent predicted, El Escorial definite ALS, presence of FTD, and presence of a *C9orf72* repeat expansion.




³ Poor prognosis based on published optimal combination of NfL and miR-181ab, in which a poor prognostic factor is defined as either (NfL > 109.8 pg/mL) or (NfL > 59.0 pg/mL and miR-181ab > 39,300 UMI)¹¹.


⁴ Poor prognosis based on recalculated combination of NfL and miR-181ab, using thresholds obtained from the current dataset; a poor prognostic factor is defined as either (NfL > 80.8 pg/mL) or (NfL > 44.8 pg/mL and miR-181ab > 24,590 UMI²).

⁵ Median serum NfL = 67.9 pg/mL

⁶ Serum NfL 4-level split is at the 33rd, 50th, and 67th percentiles (44.8 pg/mL, 67.9 pg/mL, and 80.8 pg/mL, respectively), i.e., tertiles and median, rather than quartiles to mimic construction of the NfL+miR18ab measure¹¹.




a**b****c**



ENCALS linear predictor score

3.5, 7, -3.19)	36	22	14	7	1	1
-5.19, -4.23)	51	43	22	9	1	0
-4.23, -3.35)	51	35	17	8	3	0
-3.35, -1.61)	50	27	11	2	0	0


Log-rank $p < 0.001$



delta-FRS at baseline, points/month

0, 0.35)	54	42	25	14	6	0
0.35, 0.6)	49	38	18	9	2	1
0.6, 0.89)	50	35	17	9	2	0
0.89, 3.05)	50	26	12	1	1	0


Log-rank $p < 0.001$



Serum NfL (pg/mL)

9, 124, 37.81)	51	42	28	17	6	0
37.81, 67.86)	51	38	20	7	2	1
67.86, 92.51)	51	34	18	6	2	0
92.51, 214.4)	50	27	6	3	1	0

Log-rank $p < 0.001$



Plasma miR-181a*b > 24590 UMIs

0, 0)	68	41	18	9	1	1
0, 1)	101	68	30	15	2	0
1, 1)	100	71	30	15	2	0

Log-rank $p = 0.016$